Pharmaceuticals company FDC announced Q3FY25 results Operating Revenue for Q3FY25 stood at Rs 464 crore, registering a 1.3% YoY growth from Rs 458 crore in Q3FY24. EBITDA for Q3FY25 stood at Rs 47 crore, down 44.3% YoY from Rs 84 crore. EBITDA Margin contracted to 10.1% from 18.3% YoY. Profit Before Tax (PBT) declined 47.5% YoY to Rs 51 crore, compared to Rs 98 crore. Profit After Tax (PAT) dropped 53.2% YoY to Rs 37 crore from Rs 79 crore. Earnings Per Share (EPS) decreased 53.2% YoY to Rs 2.28, compared to Rs 4.86. Management Commentary: The company delivered revenue growth of 9.1% in 9MFY25, driven by robust performance across all business segments, except for US Formulations. The export formulations business witnessed a 20.7% YoY decline in 9MFY25, primarily due to lower sales in the US market. On the other hand, the API business demonstrated strong momentum, recording a 25.6% YoY growth in Q3FY25 and 25.1% YoY growth in 9MFY25. EBITDA for Q3FY25 and 9MFY25 was impacted by lower sales in export formulation business, price reduction in the Electral range of products, driven by NLEM price revisions changes in the product mix, and higher employee costs. Result PDF